Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study)

Zeuschner P, Hoelters S, Stoeckle M, Seliger B, Mueller A, Bachmann HS, Gruenwald V, Christoph DC, Stenzl A, Grimm MO, Bruening F, Goebell P, Augustin M, Roos F, Harde J, Benz-Rued I, Staehler M, Junker K (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Oncology Research and Treatment Karger Publishers

Publisher: KARGER

City/Town: BASEL

Pages Range: 99-99

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Peter Goebell Urologische Klinik

Involved external institutions

Universität des Saarlandes (UdS)

Germany (DE) Universitätsklinikum Jena

Germany (DE) iOMEDICO AG

Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School

Germany (DE) Universitätsklinikum Tübingen

Germany (DE) Paracelsus Medizinische Privatuniversität

Austria (AT) Universität Witten/Herdecke

Germany (DE) Universitätsklinikum Essen

Germany (DE) Ludwig-Maximilians-Universität (LMU)

Germany (DE) Martin-Luther-Universität Halle-Wittenberg (MLU)

Germany (DE) Philipps-Universität Marburg

Germany (DE)

How to cite

APA:

Zeuschner, P., Hoelters, S., Stoeckle, M., Seliger, B., Mueller, A., Bachmann, H.S.,... Junker, K. (2022). Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study). In ONCOLOGY RESEARCH AND TREATMENT (pp. 99-99). BASEL: KARGER.

MLA:

Zeuschner, Philip, et al. "Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2022. 99-99.

BibTeX: Download